Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 18 January 2026 - 20 January 2026

Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

New York, Jan 20, 2026, 10:57 (EST) — Regular session Eli Lilly and Company shares (LLY) nudged up Tuesday following news of a U.S. FDA Breakthrough Therapy designation for its experimental ovarian-cancer drug. The stock traded around $1,040.38, up roughly 0.2%, after starting the session at $1,020 and dipping to a low of $1,019.66. Meanwhile, the SPDR S&P 500 ETF…
20 January 2026
····
RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

New York, Jan 20, 2026, 10:20 ET — Regular session. RAPT Therapeutics shares jumped about 64% Tuesday, reaching $57.54 in early Nasdaq action. The uptick followed Britain’s GSK unveiling a cash acquisition offer of $58 per share for the U.S. biotech firm. GSK’s deal values RAPT at $2.2 billion, securing a promising experimental food allergy treatment as drugmakers race to…
20 January 2026
·····
Novo Nordisk stock drops in Copenhagen as Wegovy pill demand gets its first real test

Novo Nordisk stock drops in Copenhagen as Wegovy pill demand gets its first real test

COPENHAGEN, Jan 19, 2026, 21:15 CET — Trading wrapped up for the day. Novo Nordisk shares slipped on Monday, giving back a portion of last week’s rally as investors weighed early demand data for the company’s new Wegovy weight-loss drug ahead of the trading week. The Copenhagen-listed B shares fell 2.8%, ending the day at 378.15 Danish crowns after moving…
19 January 2026
····
AstraZeneca share price slips in London as tariff threat rattles markets; EMA review and earnings in focus

AstraZeneca share price slips in London as tariff threat rattles markets; EMA review and earnings in focus

London, Jan 19, 2026, 19:29 (GMT) — Market closed. AstraZeneca PLC shares closed Monday down 1.15%, falling to 13,890 pence (£138.90) following a late selloff that dragged the price near the session low. The stock swung between 13,890 and 14,186 pence during the day. (Investing) London shares slipped after U.S. President Donald Trump warned of fresh tariffs on Britain and…
19 January 2026
····
Roche stock price slips in Zurich as tariff shock shakes markets — what investors watch next

Roche stock price slips in Zurich as tariff shock shakes markets — what investors watch next

Zurich, Jan 19, 2026, 18:01 CET — Market closed Roche Holding’s non-voting equity securities slipped 0.6% to close at 346.80 Swiss francs on Monday, retreating slightly from recent highs. The shares finished just shy of their one-year top at 349.7 francs, according to market data. (MarketScreener) With the Swiss market closed today, attention turns to the upcoming session and what…
19 January 2026
····
AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs

AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs

New York, January 19, 2026, 11:19 EST — Market closed. AbbVie Inc shares ended Friday at $214.35, slipping $2.44, or roughly 1.1%. This drop came after AbbVie and partner Genmab announced their blood cancer drug epcoritamab did not demonstrate a clear overall-survival benefit in a late-stage trial. (Reuters) U.S. markets were closed Monday for Martin Luther King Jr. Day, giving…
19 January 2026
······
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

New York, Jan 19, 2026, 10:08 EST — Market closed Eli Lilly and Company shares drew attention heading into Tuesday’s U.S. session, following a Friday close in the green. Investors digested new developments in the obesity-drug sector, a key driver behind the drugmaker’s recent surge. The key question now: does the early appetite for new, easier-to-swallow weight-loss pills alter the…
19 January 2026
····
Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

COPENHAGEN, Jan 18, 2026, 21:16 CET — Market closed. Novo Nordisk A/S Class B shares (NOVOb.CO) surged 6.49% on Friday, closing at 388.9 Danish crowns after hitting a high of 391.3 crowns during the session. The stock is set to reopen Monday, with traders reacting to the latest Wegovy news. (Investing) Investors are weighing whether Novo’s once-daily Wegovy pill is…
18 January 2026
·······
Merck stock (MRK) heads into a holiday pause as FDA fast-review program draws scrutiny

Merck stock (MRK) heads into a holiday pause as FDA fast-review program draws scrutiny

New York, Jan 18, 2026, 14:53 EST — Market closed. Merck & Company, Inc. shares closed Friday at $108.83, slipping 1.9%. U.S. markets will be shut Monday for Martin Luther King Jr. Day. (Yahoo Finance) Investors now have a few days to weigh a growing regulatory issue for major drug companies: just how much influence the FDA’s drive for quicker…
18 January 2026
·····
Novartis stock price: NOVN ends higher on FDA Breakthrough tag for Sjögren’s drug ianalumab — what to watch next week

Novartis stock price: NOVN ends higher on FDA Breakthrough tag for Sjögren’s drug ianalumab — what to watch next week

Zurich, January 18, 2026, 20:45 CET — The market has closed. Novartis shares rose close to 1% on Friday after the Swiss pharma giant announced that U.S. regulators had granted a Breakthrough Therapy designation to ianalumab, its drug candidate for Sjögren’s disease. The stock finished at 115.60 Swiss francs on the SIX Swiss Exchange. (MarketWatch) The designation is important because…
18 January 2026
····
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

New York, Jan 18, 2026, 11:03 EST — Market closed AbbVie’s stock dropped on Friday after partner Genmab announced that a late-stage trial of epcoritamab failed to meet its primary endpoint of improving overall survival in blood cancer patients. AbbVie closed at $214.35, down 1.1%. Genmab’s U.S.-listed shares tumbled over 7%. The companies said they still expect data from two…
18 January 2026
·······
Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Copenhagen, Jan 18, 2026, 13:52 CET — Market closed. Shares of Novo Nordisk jumped 6.49% to 388.90 Danish crowns on Friday, marking their biggest daily gain in weeks. The surge came after new demand signals for its Wegovy obesity drug and a UK approval for a higher Wegovy dose brought the stock back into focus for investors. (MarketWatch) This stock…
18 January 2026
····
1 2 3 4 … 45

Stock Market Today

  • Pro Medicus Leverages US Market to Strengthen Competitive Edge in Health-Tech
    January 22, 2026, 5:15 AM EST. Pro Medicus (ASX:PME), known for its advanced radiology imaging software and AI capabilities, is strengthening its position in the US hospital market through long-term contracts. The company competes effectively against larger legacy vendors, supporting its premium valuation despite recent share price declines. Investor focus centers on Pro Medicus' ability to sustain contract wins, margins, and cash flow ahead of its February 12, 2026 earnings report. Market sentiment remains fragile amid high valuation risks and expectations. Divergent fair value estimates, ranging from A$68.65 to over A$500, highlight varying investor perspectives on its growth prospects and US footprint. Pro Medicus' premium positioning in the specialized health-tech arena underpins its broader investment narrative.
Go toTop